PATH | VRL
Menu

A Combination Vaccine Consisting of Three Live Attenuated Enterotoxigenic Escherichia coli Strains Expressing a Range of Colonization Factors and LTB is Well Tolerated and Immunogenic in a Placebo-Controlled Double-Blind Phase 1 Trial in Healthy Adults

This article, published in Clinical and Vaccine Immunology, describes the results of a Phase 1 trial of a trivalent, live attenuated enterotoxigenic Escherichia coli vaccine candidate, ACE527. The study indicated that ACE527 had a strong safety profile and promising initial immunological data, warranting further clinical testing.

Author: Harro C, Sack D, Bourgeois AL, et al.

Published: 2011

» Visit web page (English)

(Located at cvi.asm.org)

Citation: Harro C, Sack D, Bourgeois AL, et al. A Combination Vaccine Consisting of Three Live Attenuated Enterotoxigenic Escherichia coli Strains Expressing a Range of Colonization Factors and LTB is Well Tolerated and Immunogenic in a Placebo-Controlled Double-Blind Phase 1 Trial in Healthy Adults. Clinical and Vaccine Immunology. 2011;18(12):2118-2127.

Resource types: Peer-reviewed journal

Diseases/vaccines: Shigellosis and enterotoxigenic Escherichia coli (ETEC)

Topics: Disease/vaccine specific information

Regions: Global